Objectives-Propylene glycol (PG) (1-2 propanediol; CAS No 57-55-6) is a low toxicity compound widely used as a food additive, in pharmaceutical preparations, in cosmetics, and in the workplace-for example, water based paints, de-icing fluids, and cooling liquids. Exposure to PG mist may occur from smoke generators in discotheques, theatres, and aviation emergency training. Propylene glycol may cause contact allergy, but there is sparse information on health eVects from occupational exposure to PG. Methods-Non-asthmatic volunteers (n=27) were exposed in an aircraft simulator to PG mist over 1 minute, during realistic training conditions. Geometric mean concentration of PG was 309 mg/m 3 (range 176-851 mg/m 3 ), with the highest concentrations in the afternoon. The medical investigation was performed both before and after the exposure (within 15 minutes). It included an estimate of tear film stability break up time, nasal patency by acoustic rhinometry, dynamic spirometry, and a doctor's administered questionnaire on symptoms. Results-After exposure to PG mist for 1 minute tear film stability decreased, ocular and throat symptoms increased, forced expiratory volume in 1 second/forced vital capacity (FEV 1 /FVC) was slightly reduced, and self rated severity of dyspnoea was slightly increased. No eVect was found for nasal patency, vital capacity (VC), FVC, nasal symptoms, dermal symptoms, smell of solvent, or any systemic symptoms. Those exposed to the higher concentrations in the afternoon had a more pronounced increase of throat symptoms, and a more pronounced decrease of tear film stability. In four subjects who reported development of irritative cough during exposure to PG, FEV 1 was decreased by 5%, but FEV 1 was unchanged among those who did not develop a cough. Those who developed a cough also had an increased perception of mild dyspnoea. Conclusion-Short exposure to PG mist from artificial smoke generators may cause acute ocular and upper airway irritation in non-asthmatic subjects. A few may also react with cough and slight airway obstruction. (Occup Environ Med 2001;58:649-655) 
Propylene glycol (PG) (1-2 propanediol; CAS nr 57-55-6) is a widely used compound because of its low toxicity 1 and lack of carcinogenic or mutagenic eVects. 2 3 It is used as a food additive, 4 in pharmaceutical preparations, 5 and in cosmetics. 3 Rarely, allergic contact sensitisation to PG in consumer products may occur, [6] [7] [8] and one case of systemic skin reactions in a PG sensitised subject after ingestion of food containing PG has been reported. 9 Also skin irritation from PG in tooth paste 10 as well as nasal and throat irritation related to PG in nasal spray has been reported. 11 12 Transdermal adsorption of PG may occur. 13 There are a few case reports on severe systemic reactions from PG in humans, including one case of coma in a premature infant 14 and two cases of acute renal tubular cell injury from pharmaceuticals disolved in PG. 15 16 The premature infant went into coma after treatment for burns with antiseptic dressings containing unusually high concentrations of PG. Ending the topical treatment resulted in complete recovery. 14 Propylene glycol is metabolised to lactic acid and pyromaleic acid, normal intermediates in human metabolism, either by oxidisation or phosphatisation. 4 Metabolic formation of PG and 2,3-butanediol has been reported in
Main messages
x Propylene glycol is is a low toxicity compound widely used in many products. x The concentration of propylene glycol mist in aviation emergency training can be high compared with other occupational exposure to this compound. x Mist from artificial smoke generators may cause ocular and upper airway irritation in non-asthmatic subjects. x A few may also react with cough and slight airway obstruction.
Policy implications
x Awareness should be spread that exposure to high concentrations of propylene glycol in workplaces and public places may cause ocular and respiratory irritation, and that sensitive subjects should be protected or avoid extreme or prolonged exposure.
alcoholic subjects, both in the presence and absence of alcohol, 17 in premature infants, 17 in diabetic patients, 17 and with specific enzyme deficiencies (congenital propionic and methylmalonic acidaemia). Also, alcohol related diols (PG and 2,3-butanediol) have been shown to cause insulin resistance in rats. 18 Occupational exposure to PG may occur in many occupational settings. The phasing out of organic solvents at work has increased the use of PG in Sweden, as it is commonly used in many water based products-such as water based paints. [19] [20] [21] [22] The annual Swedish consumption (8 million inhabitants) of PG is between 13 200 and 13 300 tonnes, and it is used in 1183 products. It is the 17th most common chemical counted as number of products in which it is used. 19 Other sources of occupational exposures include aircraft deicing work, where both ethylene glycol 23 and PG are used, 23 and exposure to glycol based cooling liquids in car engines. 24 Also, PG is commonly used in artificial smoke generators in discotheques, theatres, and emergency training. In connection with use of smoke generators in aviation emergency training, being a part of the basic education of pilots and flight attendants at Scandinavian Airline Systems (SAS), concern was raised about possible respiratory eVects from this exposure There is sparse published information on irritative or respiratory eVects of PG in humans. 25 Recently, clinical methods that can be applied in exposure studies have become available, including measurement of tear film stability break up time, 26 27 and nasal patency by acoustic rhinometry. [28] [29] [30] These methods have been applied to study transient physiological eVects at controlled exposures to volatile organic compounds. Decreased nasal patency has been reported at exposure to a mixture (4 h; 10 mg/m 3 ) of 22 diVerent volatile organic compounds, not including PG. 31 In another experimental study, exposure to a mixture of PG and three glycol ethers induced ocular symptoms, but did not aVect tear film stability, nasal patency, or lung function. 32 The aim of the investigation was to study eVects of an experimental exposure to PG mist, at exposure levels occurring during normal aviation emergency training. The physiological eVects studied included tear film stability, nasal patency, and lung function, as well as subjective symptoms. The study was approved by the ethics committee of the Medical Faculty of Uppsala University.
Material and methods

STUDY POPULATION
Healthy non-asthmatic volunteers (n=27), 22 men and five women, were examined medically before and after exposure to PG mist. Most were pilots working in civil aviation. Mean (SD) age of the group was 44 (11) years, 22% were current smokers, 44% were ex-smokers. In total, 30% had a history of atopy, 15% had hay fever, 15% had a history of childhood eczema, but none reported allergy to furry animals. In total, two women and six men had a history of atopy, whereas three women and 16 men did not have atopy, a non-significant but numerically higher occurrence of atopy among the women. None had ever had any respiratory disorders, including asthma or chronic bronchitis diagnosed by a doctor, and none had any febrile respiratory infection the week before the investigation. The subjects were naive, in that none had previous occupational exposure to PG. The investigations were done at normal aviation emergency training, during 1 week in March 1998, before the pollen season had started in mid-Sweden. The flight simulator belonged to a training centre of the flight academy of the Scandinavian Airline System (SAS). The artificial smoke generator was placed in the flight simulator, with a commercial PG solution for smoke generation. The exposure was performed as a part of the regular training schedules for pilots, aiming to train pilots for evacuation at fire emergency situations.
ASSESSMENT OF PERSONAL FACTORS
One general medical questionnaire was used to gather information on personal factors, including medical disorders, medication, occupational data, the home environment, and smoking habits. [28] [29] [30] Atopy was defined as having a history of childhood eczema or current history of allergy related to exposure to common IgE mediated allergens in Sweden (tree pollen, grass pollen, or furry animals). Current smoker was defined as reporting actual smoking in the interview (>1 cigarette/day), or stopping smoking less than 1 year ago.
INFORMATION ON CURRENT SYMPTOMS
Information on current symptoms was obtained from two questionnaires used in previous investigations. The first questionnaire contained 10 rating scales on current ocular, nasal, throat symptoms, dyspnoea, malodour, and systemic symptoms. 33 Answers were given on a 100 mm visual analogue rating scale (VASscale) adapted from Kjellberg et al, 34 graded from "not at all" to "almost unbearable" . The second questionnaire contained 23 yes or no questions on diVerent types of ocular, respiratory, and dermal symptoms, as well as systemic symptoms-for example, headache, nausea, and fatigue. 30 Both questionnaires were administered before and after the exposure to PG.
ASSESSMENT OF TEAR FILM STABILITY
Tear film stability was estimated by a standardised method, self reported tear film stability break up time measuring the time the subject could keep the eyes open without pain, when watching a fixed point at the wall. The method is mentioned in our introduction as tear film stability and has been used previously. It has been shown to correlate well with the fluoresceine method for detection of tear film stability. 26 27 Moreover, it has been shown that tear film stability is lower in subjects reporting ocular symptoms. were measured with a Vitalograph (Vitalograph, Buckingham, England) which was calibrated daily. Also, FEV 1 /FVC was calculated. All the tests were carried out in a standardised way with the same spirometer, by a trained nurse. To avoid disturbance of nasal patency, a nose clip was not used. The measurements were performed three times on each subject, and the highest values were noted. A test was considered adequate when the deviation between the two best tests were less than 5%. The results were expressed as a percentage of normal values based on standardisation to age, sex, height, smoking habits, and body mass using reference values from Uppsala.
TEST SEQUENCE
All physiological measurements and questionnaires were administered by a physician, in a modern oYce building, with a general ban on smoking indoors. Moreover, smokers were not allowed to smoke during the test period, which started 15 minutes before the exposure, when the subject was asked to sit down. During this time, the tear film stability test was performed first, then the two symptom questionnaires. After about 5 minutes, acoustic rhinometry was performed, then the dynamic spirometry. Then the subjects entered the smoke training unit, were exposed to PG mist for 1 minute, and went out to sit down and wait for repeated medical investigation. The same test sequence was applied before and after the exposure to PG, and was completed within 15 minutes of the exposure. When all testing was finished, the general medical questionnaire was answered.
The tests were performed during 2 days from 0930 to 1500, with a lunch break from 1200 to 1300.
ASSESSMENT OF EXPOSURE
Room temperature and relative air humidity was measured by an Assman psychrometer. Propylene glycol in the flight simulator was sampled by pumped sampling, on a synthetic polymer tube (XAD-7; SKC 226-95, SKC, USA). The sampling time was 1 minute, and the sampling rate was 200 ml/min. The XAD-7 tube was desorbed with 1 ml of methylene chloride, and analysed for PG, with a method described already. 36 A recovery of 100% of PG on the XAD tube was assumed, as was demonstrated for higher concentrations of PG in earlier desorbtion eYciency tests. 36 To control for possible overloading of the sorbent tubes by PG, both the measuring layer and the control layer of the tubes were analysed. As it was a possibility that particulate PG mist could be adsorbed on the glass wool plug in the inlet of the sampling tubes, the glass wool was desorbed separately with another 1 ml of methylene chloride.
Exposure to formaldehyde in the flight simulator was measured by pumped sampling on glass fibre filters impregnated with 2,4-dinitrophenyl hydrazine (2,4-DNF), at a flow rate of 200 ml/min for 4 hours. 37 The filters were analysed by liquid chromatography. To detect other specific volatile organic compounds in the flight simulator, pumped sampling on a conventional charcoal sorbent tube (SKC 226-01) was performed (4 h; 200 ml/min). The charcoal tube was desorbed with 1 ml carbon disulfide. Both PG and other specific compounds were analysed by means of a Hewlett Packard 5890 gas chromatograph equipped with a mass selective detector (HP 5970) (GC-MS), using a 50 metre cross linked methyl silicone capillary column (HP-1, 
Results
EXPOSURE MEASUREMENTS
Room temperature was 22.0ºC-22.5ºC, and mean relative air humidity in the flight simulator was 34%. Eleven 1 minute measurements of PG were performed. The geometric mean concentration of PG in the flight simulator was 309 mg/m 3 (GSD=1.7). Arithmetic mean concentration of PG was 360 mg/m 3 (range 176-851 mg/m 3 ), with an arithmetic mean exposure of 220 mg/m 3 in the morning, and 520 mg/m 3 in the afternoon. The distribution of the 11 point measurements over the day can be seen in figure 1 . Most detected PG was in the measuring layer of the sampling tube, only 5%-10% was detected in the control layer, and <1% was found in the glass wool plug in the inlet of the tube. Low concentrations of formaldehyde were detected in the flight simulator (29 µg/m 3 ), but no other volatile organic compounds.
SYMPTOMS
The most common annoyance after the exposure were ocular and throat irritation as measured by the VAS scales (table 1) . When analysing changes of VAS ratings, a significant increase of ocular irritation (p<0.001), throat irritation (p<0.001), and dyspnoea (p=0.048) was found, but there were no eVects on solvent smell or other symptoms.
The most common symptoms were a sensation of sore and dry eyes, throat dryness, and irritative cough, as measured by the more detailed symptom questionnaire, requesting a yes or no answer (table 2) . When grouping the symptoms for diVerent organs, a significant increase was found for ocular (p=0.005) and throat symptoms (p<0.001). Nine subjects without previous symtoms (36%) developed at least one ocular symptom after exposure to PG, and 14 (64%) developed throat symptoms. Two reported appearance of nasal catharr and one got nasal itching, but none reported sneezing or nasal obstruction after the exposure. None reported appearance of headache, nausea, or breathing diYculties after exposure to PG, and there was no net change in reporting of fatigue. One subject reported the appearance of itching on the hands, and another reported disappearance of facial skin rash after the exposure to PG mist.
There were some indications that women and those with a history of atopy seemed to be more sensitive to exposure to PG, for some types of symptoms, but the number of women (n=5) and subjects with atopy (n=8) were small. In total, 29% of men and 80% of women reported the development of throat symptoms, but there were no sex diVerence for development of ocular symptoms. Moreover, 50% of those with atopy, and 11% of those without atopy reported development of least one ocular symptom. Finally, 100% of those with atopy, but only 28% of those without atopy reported development of throat symptoms after exposure to PG.
PHYSIOLOGICAL INVESTIGATIONS
All participated in the acoustic rhinometry and the lung function test. One could not participate in the measurement of tear film stability due to nervous blinking. A significant decrease of tear film stability was found after exposure to PG, with a reduction of mean tear film stability break up time from 38 to 29 seconds (p=0.02), and the decrease of tear film stability was similar in men and women. The diVerence in tear film stability before and after the exposure was the same (mean decrease 6 s) in those who developed and those who did not develop ocular symptoms. When comparing tear film stability after the exposure, however, those who developed ocular symptoms had numerically lower tear film stability (mean 27 s) than those who did not (mean 34 s). The two people with ocular symptoms before the exposure had the greatest decrease of tear film stability (mean decrease 38 s). No significant changes in any measures of nasal patency were found after exposure to PG (table 3) . Most of the lung function values remained unchanged after exposure to PG, but there was a minor numerical decrease of FEV 1 from 103% to 102% at exposure, and a small but significant decrease of FEV 1 /FVC (p=0.049). Mean VC was unchanged after the exposure, whereas FVC was slightly increased (table 4). None of the 27 participants had an initial lung function value (FEV 1 ) below 80% of predicted value, but one got a 77% value for FEV 1 after the exposure. The mean decrease of FEV 1 and FEV 1 /FVC was similar in subjects with and without a history of atopy. Moreover, there were no significant association between a decrease in FEV 1 , and development of mild dyspnoea (measured by the rating scales) in the total material A few, however, reacted with cough, mild airway obstruction, and mild dyspnoea. There were four subjects (16%) who developed irritative cough after the exposure. All were non-smoking men, without any history of allergies. They had an average reduction in FEV 1 of 5%, compared with a 0% reduction of FEV 1 among those who did not develop a cough. Moreover, those four subjects had an increase in self rated dyspnoea of 13% on the analogue scale, whereas those who did not develop cough only had a 1% increase of dyspnoea, a significant diVerence between the two groups (p<0.01).
DOSE-EFFECT RELATIONS
The investigation was not a controlled exposure chamber test, but a physiological investigation performed during exposure conditions occurring when PG mist was used in aviation training. The mean exposure measurements showed that there were higher exposures (520 mg/m 3 ) in the afternoon than in the morning, before the lunch break (220 mg/m 3 ). These diVerences made it possible to evaluate possible dose-eVect relations comparing changes from before to after exposure in those nine subjects exposed in the afternoon with those 18 exposed in the morning. A dose-eVect relation was found for tear film break up time, with a 6 second average decrease in the low exposure group and a 13 second decrease in the high exposure group. Moreover, 47% in the low exposure group but 100% in the high exposure group reported development of throat dryness, and the rating of throat symptoms on the VAS scale were higher in the highly exposed group. By contrast, no dose-eVect relations were found for ocular or nasal symtoms, dyspnoea, nasal patency, or FEV 1 % (table 5) .
Discussion
The design was experimental and showed acute eVects on ocular and throat symptoms, and decreased tear film stability in nonasthmatic subjects after 1 minute exposure to PG mist from an artificial smoke generator. A few reacted with a small lower airway obstruction, cough, and mild dyspnoea. Moreover, there were indications of a dose-eVect relation for throat symptoms and impairment of tear film stablility. There were some indications that women and subjects with a history of atopy reported more of some types of symptoms after the exposure. These results agree with a population study, suggesting that women and subjects with atopy are more sensitive to emissions from indoor paint. 38 The physiological methods in the chosen acute eVect test battery have been used in previous epidemiological 30 and experimental investigations. 31 As there were few subjects participating in this type of emergency training at each time, the number of participants was limited. The study was based on non-asthmatic volunteers, participating in the exposure as a part of their occupational training. The exposure time was short, but relevant to the exposure time used in aviation emergency training. Despite the limitations of the study, limited power, short exposure time, and exclusion of asthmatic people, we showed significant eVects of airborne exposure to PG mist.
The exposure concentration of PG (geometric mean 309 mg/m 3 ) was quite high, compared with other exposure measurements of this compound in work environments. Exposure ), but no measurable exposure to PG was found in motor servicing work. 24 The exposure measurements showed that the concentrations of other volatile organic compounds in the flight simulator were very low, and the concentration of formaldehyde was similar to that found in mid-Swedish dwellings. 39 To our knowledge, this is the first study of irritative and respiratory eVects of occupational exposure to airborne PG. There are some earlier exposure studies in animals. In one study, 19 rats were exposed by nose only inhalation to 0, 160 (low), 1000 (medium), and 2200 (high) mg/m 3 concentrations of PG, 6 hours/day 5 days/week for 90 days. There was a significant increase in the number of goblet cells in the nasal passages of the medium and highly exposed animals. It was concluded that this exposure to PG caused nasal haemorrhage and ocular discharge in a high proportion of animals, possibly due to dehydration of the nares and eyes. 40 In one study of the eVects of organic solvents to induce erythema, no eVect was found on dermal blood flow measured by Doppler flowmetry, after dermal application of concentrated PG in humans. 41 In another study, children were exposed to airborne PG (mean concentration 69 mg/m 3 , maximum 94 mg/m 3 ) at air sterilisation, continuously during several weeks. No negative eVects were found on mucous membranes in the upper respiratory tract. 42 There are some indications that PG in tooth paste and nasal spray may cause mucosal irritation in humans, but the relevance of these findings for occupational exposure to PG is unclear. When comparing dermal irritation from four commercial toothpastes, three with PG and one without PG, less irritation was found for the toothpaste without PG. 10 When comparing airway symptoms in subjects with allergic rhinitis who used two diVerent nasal sprays, less nasal burring, stinging, and throat irritation was found when the concentration of PG was reduced in the newer formulation of nasal spray. 12 Similar results were found in another study that showed improved nasal airflow, decrease of nasal eosinophilia, and less nasal burning and stinging with a new formulation of nasal spray containing less PG. 11 Also, one recent case report describes asthma crisis and cough induced by PG. 25 There are three experimental studies on acute eVects of emissions from water based paints containing both PG and other volatile organic compounds-for example, glycol ethers. In one study, 30 non-asthmatic subjects were exposed for 4 hours to a mixture of PG (10 mg/m ). EVects on ocular symptoms, but no eVect on tear film stability, nasal patency measured by acoustic rhinometry, or lung function were found. 32 In another study, 18 non-asthmatic subjects were exposed for 2 hours to emissions from two diVerent formulations of water based paint, with emissions from viscosed water as a control. The exposure to PG was 0.13 mg/m 3 with the old formulation, and 0.03 mg/m 3 in the new formulation, expressed as toulene equivalents. The new formulation had a reduced emission of other volatile organic compounds, including 2-methyl-1-propanol, 2-butoxy-ethanol, and diisobutyl glutarate. None of the two paint formulations had a significant eVect on tear film stability, nasal patency measured by acoustic rhinometry, or concentration of biomarkers of inflammation in nasal lavage. The old paint formulation induced some acute symptoms, had more smell, and induced a minor acute airway obstruction, whereas the new paint had no such eVects. 43 Finally, 17 asthmatic subjects with previous exacerbation of symptoms on exposure to paint or other odours were exposed to emissions from two diVerent formulations of water based paints. The new formulation, a volatile organic compound free paint, caused less wheeze and breathlessness, and less airway obstruction. 44 Despite the common use of PG in many commercial and industrial products, there are few studies on irritative eVects in humans from airborne exposure to this compound. As PG is commonly used in artificial smoke generators in discotheques, theatres, and emergency training, possible adverse eVects of such exposure can be of public interest, particularly for sensitive subjects. Our measurements showed that exposure to PG can be high from smoke generators, higher than in other occupational applications. We conclude from our results that short exposures to PG mist from smoke generators may cause acute irritative ocular and upper airway eVects in non-asthmatic subjects, and some symptoms were more common in women and subjects with atopy. A few may also react with minor lower airway obstruction, cough, and mild dyspnoea. Recent experimental studies have shown that there are subjects with with increased sensitivity to trigeminal irritants (sensory hyperreactivity). These subjects react with cough after provocation with capsaicin solutions, and the reaction can be blocked by lidocain, which inhibits nerve transmission in the sensory nerves. 45 Moreover, such subjects may react with cough and asthma-like symptoms after provocation to irritants. 46 Thus, sensory hyperreactivity could be one mechanism behind the development of a combination of cough, slight airway obstruction, and mild dyspnoea in a few of those exposed to PG mist. As exposure to PG mist may occur both in workplaces and certain public places, studies on respiratory eVects of PG in subjects with obstructive respiratory disorders or sensory hyperreactivity seem relevant. 
